GNH USA

Europe — EMA

Miglustat Bluefish

GNH USA supplies Miglustat Bluefish (Miglustat), a glucosylceramide synthase inhibitor for Gaucher disease type 1 and Niemann‑Pick disease type C.

Miglustat

Request sourcing

1
Pack/s

What is Miglustat?

Miglustat, the active ingredient in Miglustat Bluefish, is a glucosylceramide synthase inhibitor presented as an oral tablet for oral use. It treats Gaucher disease type 1 and Niemann‑Pick disease type C in patients for whom substrate reduction therapy is appropriate, and it complies with European Union pharmaceutical standards.

GNH USA supplies Miglustat Bluefish as a licensed, GDP‑compliant international pharmaceutical supplier serving hospitals, pharmacies and clinics worldwide through a validated supply chain.

What is Miglustat used for?

Miglustat is used in lysosomal storage disorders that involve glycosphingolipid accumulation.

- Gaucher disease type 1: reduces spleen and liver size, improves blood counts and bone disease. - Niemann-Pick disease type C: slows neurological decline and stabilizes disease progression.

What are the side effects of Miglustat?

Miglustat may cause a range of adverse reactions, which are grouped by frequency and severity.

Common Side Effects: - Diarrhea - Nausea - Abdominal pain - Weight loss - Flatulence - Headache

Serious or Rare Side Effects: - Pancreatitis - Severe hypoglycemia - Hepatic dysfunction - Anaphylactic reaction - Peripheral neuropathy - Severe depression or suicidal ideation

What precautions apply to Miglustat?

When prescribing Miglustat, clinicians should observe several precautionary measures to ensure patient safety.

- Monitor liver function: obtain baseline liver enzymes and repeat periodically. - Assess gastrointestinal tolerance: manage diarrhea and nausea promptly. - Evaluate weight: monitor for unintended weight loss and provide nutritional support. - Review pancreatic symptoms: discontinue if signs of pancreatitis develop. - Avoid in patients with known hypersensitivity to Miglustat or excipients. - Store at ambient temperature: keep below 25°C, protect from moisture and light.

What does Miglustat interact with?

Miglustat can interact with other medicines, requiring attention to avoid clinically significant effects.

Major Interactions (Avoid): - Strong CYP3A4 inhibitors: may increase Miglustat exposure and toxicity. - Oral antidiabetic agents (e.g., sulfonylureas): heightened risk of hypoglycemia. - Concurrent substrate‑reduction agents: additive metabolic burden.

Moderate Interactions (Monitor Closely): - Antacids containing aluminum or magnesium: may reduce oral absorption. - Warfarin: potential alteration of INR, necessitating closer monitoring. - Hormonal contraceptives: possible reduction in efficacy, advise alternative contraception.

Frequently asked questions

What is Miglustat Bluefish used for?+
Miglustat Bluefish is an oral substrate‑reduction therapy indicated for the treatment of Gaucher disease type 1 and Niemann‑Pick disease type C. In these lysosomal storage disorders, the drug helps lower the accumulation of glycosphingolipids, thereby improving organ size, blood parameters, and neurological outcomes when used under specialist supervision.
How does Miglustat work?+
Miglustat works by inhibiting glucosylceramide synthase, the enzyme responsible for the first step in glycosphingolipid synthesis. By blocking this pathway, the drug reduces the production of glucosylceramide and related lipids that build up in lysosomes, helping to restore normal cellular function in affected patients.
What is the usual dose of Miglustat Bluefish?+
The dosage of Miglustat Bluefish is individualized and must be prescribed by a qualified healthcare professional. The prescriber determines the appropriate dose based on the patient’s age, weight, disease severity, and renal function, and may adjust it over time according to clinical response and tolerability.
Is Miglustat safe in pregnancy or breastfeeding?+
Safety data for Miglustat in pregnancy and lactation are limited, and the product is classified as having an unknown pregnancy category. It should only be used during pregnancy or while breastfeeding if the potential benefit to the mother outweighs any possible risk to the fetus or infant, and after thorough discussion with a specialist.
How do I order Miglustat Bluefish from GNH USA?+
To order Miglustat Bluefish, submit an enquiry on the product page at gnh-usa.com, specifying the required quantity. GNH USA works with hospitals, pharmacies and procurement teams worldwide, verifies trade or institutional credentials, and then provides pricing, availability, shipping details (including any cold‑chain requirements), and the necessary import documentation.
How does Miglustat compare with the main alternative therapy?+
The primary alternative to Miglustat is enzyme‑replacement therapy (ERT) such as imiglucerase. While ERT supplies the missing enzyme intravenously, Miglustat is an oral small‑molecule that reduces substrate synthesis. Miglustat offers a convenient oral route but may have more gastrointestinal side effects, whereas ERT avoids those but requires regular infusions.
What are the storage and handling requirements for Miglustat Bluefish?+
Miglustat Bluefish should be stored at ambient temperature, preferably below 25 °C. Keep the tablets in the original container, protect them from moisture and direct sunlight, and ensure the packaging remains sealed until use to maintain product stability.
How is Miglustat administered?+
Miglustat is taken orally, usually with a glass of water. It can be administered with or without food, but taking it with meals may help reduce gastrointestinal discomfort. The exact dosing schedule is set by the prescribing physician and should be followed exactly as instructed.
What are the most serious risks to watch for while taking Miglustat?+
Serious risks associated with Miglustat include pancreatitis, severe hypoglycemia, hepatic dysfunction, anaphylactic reactions, peripheral neuropathy, and severe depression or suicidal thoughts. Patients should be educated to seek immediate medical attention if they experience abdominal pain, sudden weight loss, jaundice, allergic symptoms, or mood changes.
Who should not use Miglustat Bluefish?+
Miglustat Bluefish is contraindicated in individuals with known hypersensitivity to Miglustat or any of its excipients. It should also be avoided in patients with severe liver disease, uncontrolled diabetes, or those who are pregnant unless the therapeutic benefit justifies the potential risk. A specialist should evaluate each case before initiating therapy.
Information provided on this page is for educational use by procurement and clinical professionals. Always consult a licensed healthcare provider for medical advice and prescribing decisions. GNH USA supplies this product subject to applicable regulatory and licensing requirements.
Send a sourcing enquiry for this product →

Product details

Drug
Miglustat
Route
Oral Use
Manufacturer
Bluefish Pharmaceuticals Ab
Origin
EU

Related products

Miglustat 100 mg/1

Miglustat 100 mg/1

Miglustat · 100 mg

Miglustat
CAPSULE
CoTherix, Inc.
USA
Zavesca 100 mg

Zavesca 100 mg

Miglustat · 100 MG

Zavesca
CAPSULE
JANSSEN INC
CANADA
Sandoz Miglustat 100 mg

Sandoz Miglustat 100 mg

Miglustat · 100 MG

Sandoz Miglustat
CAPSULE
SANDOZ CANADA INCORPORATED
CANADA
Miglustat Accord

Miglustat Accord

Miglustat

Accord Healthcare Limited
EU